Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.

Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL.

AJNR Am J Neuroradiol. 2019 Jul;40(7):1132-1139. doi: 10.3174/ajnr.A6110. Epub 2019 Jun 27.

PMID:
31248863
2.

Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.

Radiology. 2019 Feb;290(2):467-476. doi: 10.1148/radiol.2019181296. Epub 2018 Nov 27.

PMID:
30480488
3.

Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2018 Sep 3;20(10):1400-1410. doi: 10.1093/neuonc/noy049.

4.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

5.

Statistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims.

Obuchowski NA, Buckler A, Kinahan P, Chen-Mayer H, Petrick N, Barboriak DP, Bullen J, Barnhart H, Sullivan DC.

Acad Radiol. 2016 Apr;23(4):496-506. doi: 10.1016/j.acra.2015.12.020. Epub 2016 Feb 18. Review.

6.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP.

Neuro Oncol. 2015 Nov;17(11):1538-9. doi: 10.1093/neuonc/nov163. Epub 2015 Sep 11. No abstract available.

7.

Metrology Standards for Quantitative Imaging Biomarkers.

Sullivan DC, Obuchowski NA, Kessler LG, Raunig DL, Gatsonis C, Huang EP, Kondratovich M, McShane LM, Reeves AP, Barboriak DP, Guimaraes AR, Wahl RL; RSNA-QIBA Metrology Working Group.

Radiology. 2015 Dec;277(3):813-25. doi: 10.1148/radiol.2015142202. Epub 2015 Aug 12.

8.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. doi: 10.3174/ajnr.A4374. Epub 2015 Jun 11.

9.

Response assessment criteria for brain metastases: proposal from the RANO group.

Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. Review.

PMID:
26065612
10.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

11.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

12.

Quantitative imaging biomarkers: a review of statistical methods for computer algorithm comparisons.

Obuchowski NA, Reeves AP, Huang EP, Wang XF, Buckler AJ, Kim HJ, Barnhart HX, Jackson EF, Giger ML, Pennello G, Toledano AY, Kalpathy-Cramer J, Apanasovich TV, Kinahan PE, Myers KJ, Goldgof DB, Barboriak DP, Gillies RJ, Schwartz LH, Sullivan DC; Algorithm Comparison Working Group.

Stat Methods Med Res. 2015 Feb;24(1):68-106. doi: 10.1177/0962280214537390. Epub 2014 Jun 11. Review.

13.

Repeatability of quantitative metrics derived from MR diffusion tractography in paediatric patients with epilepsy.

Paldino MJ, Hedges K, Rodrigues KM, Barboriak DP.

Br J Radiol. 2014 May;87(1037):20140095. doi: 10.1259/bjr.20140095. Epub 2014 Feb 24.

14.

A fully automatic extraction of magnetic resonance image features in glioblastoma patients.

Zhang J, Barboriak DP, Hobbs H, Mazurowski MA.

Med Phys. 2014 Apr;41(4):042301. doi: 10.1118/1.4866218.

PMID:
24694151
15.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

16.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

17.

Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.

Craciunescu OI, Yoo DS, Cleland E, Muradyan N, Carroll MD, MacFall JR, Barboriak DP, Brizel DM.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e345-50. doi: 10.1016/j.ijrobp.2011.05.059. Epub 2011 Oct 8.

PMID:
21985945
18.

Gliosarcoma metastatic to the leptomeninges and dura.

Mansouri B, Barboriak DP, Kilani RK.

J Neuroimaging. 2013 Apr;23(2):245-7. doi: 10.1111/j.1552-6569.2011.00641.x. Epub 2011 Sep 1.

PMID:
21883625
19.

Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.

Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD.

Neurosurgery. 2011 Sep;69(3):668-76. doi: 10.1227/NEU.0b013e3182181ba8.

20.

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP.

Br J Radiol. 2012 Apr;85(1012):382-9. doi: 10.1259/bjr/24774491. Epub 2011 Jan 11.

21.

Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.

Paldino MJ, Wong TZ, Reardon DA, Friedman HS, Barboriak DP.

Br J Radiol. 2011 Apr;84(1000):327-33. doi: 10.1259/bjr/48528504. Epub 2010 Oct 19.

22.

Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.

Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TP, van Bruggen N.

Magn Reson Med. 2010 Aug;64(2):408-17. doi: 10.1002/mrm.22399.

23.

An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.

Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE.

Magn Reson Med. 2010 May;63(5):1366-75. doi: 10.1002/mrm.22335.

24.

Trichothiodystrophy with dysmyelination and central osteosclerosis.

Harreld JH, Smith EC, Prose NS, Puri PK, Barboriak DP.

AJNR Am J Neuroradiol. 2010 Jan;31(1):129-30. doi: 10.3174/ajnr.A1665.

26.

Magnetic resonance assessment of response to therapy: tumor change measurement, truth data and error sources.

Jackson EF, Barboriak DP, Bidaut LM, Meyer CR.

Transl Oncol. 2009 Dec;2(4):211-5.

27.

Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources.

Meyer CR, Armato SG, Fenimore CP, McLennan G, Bidaut LM, Barboriak DP, Gavrielides MA, Jackson EF, McNitt-Gray MF, Kinahan PE, Petrick N, Zhao B.

Transl Oncol. 2009 Dec;2(4):198-210.

28.

Ruptured maxillary retention cyst: cause of unilateral rhinorrhea after trauma.

Hoang JK, Smith EC, Barboriak DP.

AJNR Am J Neuroradiol. 2009 Jun;30(6):1121-2. doi: 10.3174/ajnr.A1457. Epub 2009 May 13.

29.

Fundamentals of quantitative dynamic contrast-enhanced MR imaging.

Paldino MJ, Barboriak DP.

Magn Reson Imaging Clin N Am. 2009 May;17(2):277-89. doi: 10.1016/j.mric.2009.01.007. Review.

PMID:
19406359
30.

Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging.

Barboriak DP, MacFall JR, Viglianti BL, Dewhirst Dvm MW.

J Magn Reson Imaging. 2008 Jun;27(6):1388-98. doi: 10.1002/jmri.21344.

31.

Hippocampal MRI signal hyperintensity after febrile status epilepticus is predictive of subsequent mesial temporal sclerosis.

Provenzale JM, Barboriak DP, VanLandingham K, MacFall J, Delong D, Lewis DV.

AJR Am J Roentgenol. 2008 Apr;190(4):976-83. doi: 10.2214/AJR.07.2407.

PMID:
18356445
33.

Chemodosimetry of in vivo tumor liposomal drug concentration using MRI.

Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW.

Magn Reson Med. 2006 Nov;56(5):1011-8.

34.

Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response.

Provenzale JM, Mukundan S, Barboriak DP.

Radiology. 2006 Jun;239(3):632-49. Review.

PMID:
16714455
35.

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR.

J Nucl Med. 2005 Jun;46(6):1042-51.

36.

Creation of DICOM--aware applications using ImageJ.

Barboriak DP, Padua AO, York GE, Macfall JR.

J Digit Imaging. 2005 Jun;18(2):91-9.

37.

Assessment of apparent diffusion coefficient in normal and degenerated intervertebral lumbar disks: initial experience.

Kealey SM, Aho T, Delong D, Barboriak DP, Provenzale JM, Eastwood JD.

Radiology. 2005 May;235(2):569-74. Epub 2005 Mar 29.

PMID:
15798157
38.

Imaging of brain tumors with diffusion-weighted and diffusion tensor MR imaging.

Barboriak DP.

Magn Reson Imaging Clin N Am. 2003 Aug;11(3):379-401. Review.

PMID:
14768725
39.

Correlation of early dynamic CT perfusion imaging with whole-brain MR diffusion and perfusion imaging in acute hemispheric stroke.

Eastwood JD, Lev MH, Wintermark M, Fitzek C, Barboriak DP, Delong DM, Lee TY, Azhari T, Herzau M, Chilukuri VR, Provenzale JM.

AJNR Am J Neuroradiol. 2003 Oct;24(9):1869-75.

40.

Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy.

Rohren EM, Provenzale JM, Barboriak DP, Coleman RE.

Radiology. 2003 Jan;226(1):181-7.

PMID:
12511688
41.

Do prolonged febrile seizures produce medial temporal sclerosis? Hypotheses, MRI evidence and unanswered questions.

Lewis DV, Barboriak DP, MacFall JR, Provenzale JM, Mitchell TV, VanLandingham KE.

Prog Brain Res. 2002;135:263-78. Review.

PMID:
12143347
42.

MR signal intensity of gray matter/white matter contrast and intracranial fat: effects of age and sex.

Kim DM, Xanthakos SA, Tupler LA, Barboriak DP, Charles HC, MacFall JR, Krishnan KR.

Psychiatry Res. 2002 Jul 1;114(3):149-61.

PMID:
12113897
43.
44.

CT perfusion scanning with deconvolution analysis: pilot study in patients with acute middle cerebral artery stroke.

Eastwood JD, Lev MH, Azhari T, Lee TY, Barboriak DP, Delong DM, Fitzek C, Herzau M, Wintermark M, Meuli R, Brazier D, Provenzale JM.

Radiology. 2002 Jan;222(1):227-36.

PMID:
11756730
45.

Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome.

Provenzale JM, Petrella JR, Cruz LC Jr, Wong JC, Engelter S, Barboriak DP.

AJNR Am J Neuroradiol. 2001 Sep;22(8):1455-61.

46.

Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate.

Chen JG, Charles HC, Barboriak DP, Doraiswamy PM.

Acta Neurol Scand Suppl. 2000;176:20-6. Review.

PMID:
11261801
47.

Serial MR imaging of pineal cysts: implications for natural history and follow-up.

Barboriak DP, Lee L, Provenzale JM.

AJR Am J Roentgenol. 2001 Mar;176(3):737-43.

PMID:
11222216
48.

Vertex epidural hematomas: imaging findings and diagnostic pitfalls.

Harbury OL, Provenzale JM, Barboriak DP.

Eur J Radiol. 2000 Dec;36(3):150-7.

PMID:
11091016
49.

Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype.

Barboriak DP, Doraiswamy PM, Krishnan KR, Vidyarthi S, Sylvester J, Charles HC.

Neurology. 2000 Jun 13;54(11):2150-3.

PMID:
10851380
50.

Comparison of patient age with MR imaging features of gangliogliomas.

Provenzale JM, Ali U, Barboriak DP, Kallmes DF, Delong DM, McLendon RE.

AJR Am J Roentgenol. 2000 Mar;174(3):859-62.

PMID:
10701639

Supplemental Content

Loading ...
Support Center